Clinical trial
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and…
NCT00343291 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00343291 |
|---|---|
| Title | A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC |
| Official title | Phase II Randomized, Open-Label Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | Cetuximab, Bevacizumab, Paclitaxel, Carboplatin |
| Enrollment | 121 |
| Start date | Dec 1, 2006 |
| Primary completion | May 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Jun 22, 2006 |
| Last update posted | Jun 7, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: